Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Name: Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
License: Public Domain

AIO-Studien-gGmbH

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

nsclc stage iv

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 234416
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.